Clinical trials: Vasculitis, Central Nervous System
Rheumatoid Arthritis, Giant Cell Arteritis
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
A single dose, two period trial where participants will be given either of 3 Tocilizumab product on Day 1 during period 1 and either one of the remaining 2 Tocilizumab products on Day 1 period 2.
- Trial name
- NCT04885829
- Testing
- Tocilizumab Prefilled Syringe
- Where
- 4 sites in Australia, India and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Syneos Health
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis
- Trial name
- PRAVDA (NCT04280601)
- Testing
- vitamin D
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Christian Pagnoux
Adrenal Insufficiency, Polymyalgia Rheumatica
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
In this double-blinded randomised placebo-controlled clinical trial, the aim is to determine the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health related…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica, Giant Cell Arteritis
- Trial name
- RESCUE (NCT05435781)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- Marianne Christina Klose
Vasculitis, CNS, Vasculitis, Cerebral
Vessel Wall Imaging for Diagnosis and Monitoring of Central Nervous System (CNS) Vasculitis
This is a prospective pilot study to determine the utility of MRI and high resolution intracranial vessel wall imaging for the diagnosis and disease activity assessment of intracranial vasculitis.
- Trial name
- NCT03166319
- Testing
- MRI, including intracranial vessel wall imaging
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Giant Cell Arteritis
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
The aim of this study is to compare the use of FDG PET/CT to Ga-68 HA-DOTATATE (abbreviated DOTATATE) PET/CT in patients with active giant cell arteritis (GCA) started on prednisone to understand if DOTATATE can identify more…
- Trial name
- NCT03812302
- Testing
- 68-Ga HA-DOTATATE PET/CT
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University of Alberta
Glomerulonephritis Acute
Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis
Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+ effector/memory T cells in urine at time of…
- Trial name
- NCT04320667
- Testing
- Flow cytometry analysis of urine samples
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Charite University, Berlin, Germany
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Vasculitis, Microscopic Polyangiitis
Alemtuzumab for ANCA Associated Refractory Vasculitis
Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among…
- Conditions
- Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis, Wegener's
- Trial name
- ALEVIATE (NCT01405807)
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Giant Cell Arteritis
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
The purpose of this study is to demonstrate the efficacy and safety of subcutaneously (s.c.) administered secukinumab 300 mg in combination with glucocorticoid taper regimen compared to placebo in combination with glucocorticoid…
- Trial name
- GigAINt (NCT05380453)
- Testing
- Secukinumab 300 mg, s.c.
- Where
- 25 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.
The goal of this observational study is to expand the knowledge about development and aggreviation of diabetes mellitus in patients with giant cell arthritis and polymyalgia rheumatica.
- Conditions
- Giant Cell Arteritis, Polymyalgia Rheumatica, Large Vessel Vasculitis
- Trial name
- NCT06011512
- Where
- Denmark
- Volunteers
- 198 people
- Sponsor
- Salome Kristensen
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Temporal Arteritis
Aetiology of TemporaL Arteritis Study
Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis.
- Trial name
- ATLAS (NCT02584517)
- Sponsor
- University of Oxford
Chronic Coronary Syndrome, Heart Failure
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation.
- Conditions
- Chronic Coronary Syndrome, Heart Failure, AMD and Macular Edema, Chronic Respiratory Failure
- Trial name
- CLEO-CD (NCT04390126)
- Testing
- life questionnaires, questionnaire
- Where
- France
- Volunteers
- 1,343 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Horton's Disease, Infectious Disease
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease.
- Conditions
- Horton's Disease, Infectious Disease, Neoplasia, Solid Tumor
- Trial name
- NCT02065297
- Testing
- 1 blood sample, 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
- Where
- 3 sites in France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
Large Vessel Vasculitis, Giant Cell Arteritis (GCA)
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes.
- Conditions
- Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
- Trial name
- DERAIL-LVV (NCT06887062)
- Testing
- Bosentan and dapagliflozin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
ANCA Associated Vasculitis (AAV)
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis.
- Trial name
- ARRIA (NCT06611696)
- Testing
- Avacopan, prednisolone and rituximab, Prednisolone and rituximab
- Where
- 22 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Chiba University
Giant Cell Arteritis
Giant Cell Arteritis and Anakinra Trial
SYNOPSIS The giant cell arteritis (GCA) is the most frequent vasculitis in people over 50 years. Despite recent progress and physiopathogenic, corticosteroids remains the standard treatment for decades with a very good initial…
- Trial name
- GiAnT (NCT02902731)
- Testing
- ANAKINRA
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two rare immune system disorders that cause the inflammation of blood vessels, or vasculitis.
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
- Trial name
- NCT00315393
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,046 people
- Sponsor
- University of Pennsylvania